Targeting BAP1: a new paradigm for mesothelioma
- PMID: 28342657
- DOI: 10.1016/j.lungcan.2017.03.005
Targeting BAP1: a new paradigm for mesothelioma
Abstract
New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary.
Keywords: BAP1; Inhibitor; Loss; Malignant mesothelioma; Mutation; Targeting.
Copyright © 2017 Elsevier B.V. All rights reserved.
Comment in
-
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma.Lung Cancer. 2017 Dec;114:103-105. doi: 10.1016/j.lungcan.2017.07.027. Epub 2017 Jul 24. Lung Cancer. 2017. PMID: 28757047 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical